Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA

Ratings ESG MSCI

Ratings AbbVie Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: AbbVie Inc.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: AbbVie Inc.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 25.84 times its estimated earnings per share for the ongoing year.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Rating Financials

AbbVie Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

AbbVie Inc. SectorUnited States

Global Valuation

-

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

-

P/E

PBR

-

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

AbbVie Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

AbbVie Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

AbbVie Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
375B -
AA
- -
909B
A
552B
BBB
332B
AA
291B
A
287B
AAA
279B
A
199B
A
179B
A
162B
AA
Average 356.53B
AA
Weighted average by Cap.
AA